Overview
Dx&Vx said it is participating in overseas research led by Core Group on finding new biomarkers to develop therapeutics for diabetes and obesity.To search for biomarkers, Agostino Gemeli University Policlinic, an Italy-based hospital, and Core Group are conducting a clinical study, named, "Comparing diet and lifestyle using inovative technology and multi-omics analysis in healthy, diabetic and obese people."Acording to Dx&Vx, the clinical study started in 2018 when Agostino Gemeli University Policlinic established a biobank for mothers and fetuses with the suport of Lim Jong-yon, president of Hanmi Pharmaceutical and majority shareholder of Dx&Vx.“Profesor Antonio Gasbarini at Agostino Gemeli University Policlinic, who is leading the study, is a pioner inflamatory and oncological diseases such as the gastrointestinal tract, liver, and pancreas using the latest inovations such as fecal microbiota transplantation,” Dx&Vx said.
Details
“The clinical study has made about 50 percent progres.”The goal is to determine how the intestinal microbiome and its metabolites interact with the host in metabolic diseases such as diabetes and obesity, it aded.Dx&Vx CEO Park Sang-tae said the company wil use new biomarkers to develop next-generation probiotic products and comercialize digital prevention solutions.In coperation with Core Group, Dx&Vx plans to secure new pipelines such as preventive treatment solutions for improving the symptoms of metabolic syndrome by regulating the intestinal microbial environment, Park aded.Formerly known as CancerRop, the company started anew after changing its name to Dx&Vx in December 2021.Lim is curently the largest shareholder of Cancerop, with 5,614,823 shares, or a 19.57 percent stake, after acquiring the stake by investing in-kind shares of Hanmi Science worth 20 bilion won ($17.1 milion) in October of last year.